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ABSTRACT
The prostate gland is subject to various disorders. The etiology and pathogenesis of these diseases remain not well understood. Moreover, despite 
technological advancements, the differential diagnosis of prostate disorders has become progressively more complex and controversial. It was 
suggested that the chromium (Cr) level in prostatic tissue plays an important role in prostatic carcinogenesis and its measurement may be useful 
as a cancer biomarker. These suggestions promoted more detailed studies of the Cr content in the prostatic tissue of healthy subjects. The present 
study evaluated by systematic analysis the published data for Cr content analyzed in prostatic tissue of “normal” glands. This evaluation reviewed 
1958 studies, all of which were published in the years from 1921 to 2020 and were located by searching the databases PubMed, Scopus, ELSEVIER-
EMBASE, Cochrane Library, and the Web of Science. The articles were analyzed and “Median of Means” and “Range of Means” were used to examine 
heterogeneity of the measured Cr content in prostates of apparently healthy men. The objective analysis was performed on data from the 28 studies, 
which included 1282 subjects. It was found that the range of means of prostatic Cr content reported in the literature for “normal” gland varies widely 
from 0.009 mg/kg to 0.34 mg/kg with median of means 0.095 mg/kg on a wet mass basis. The level of intra-prostatic metal does not depend on age 
and androgen status. Finally, because of small sample size and high data heterogeneity, we recommend other primary studies be performed.
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INTRODUCTION
The prostate gland is subject to various disorders and of them chronic 
prostatitis, benign prostatic hyperplasia (BPH), and prostate cancer 
(PCa) are extremely common diseases of aging men [1-3]. The etiology 
and pathogenesis of these diseases remain not well understood. A 
better understanding of the etiology and causative risk factors are 
essential for the primary prevention of these diseases.
In our previous studies, the significant involvement of trace elements 
(TEs) in the function of the prostate was found. [4-15]. It was also shown 
that levels of TEs in prostatic tissue, including chromium (Cr), can play a 
significant role in etiology of PCa [16-20]. Moreover, it was demonstrated 
that the changes of some TE levels and Zn/TE ratios, including Zn/Cr 
ratio, in prostate tissue can be used as biomarkers [21-27].
Cr has been studied in medicine since the end of the 19th century, 
when carcinogenic effects of hexavalent Cr(VI) were discovered. It was 
indicated very low levels of Cr in human prostatic tissue (0.05 mg/kg 
of wet tissue) in study published about 60 years ago [28]. However, 
recently Banaś et al. [29] found that the Cr mass fraction in human 
prostate is two orders of magnitude higher than previously published 
results (5.0 mg/kg of wet tissue). This finding allowed made the 
inference that the prostate gland accumulates Cr, because the level of 
metal in prostate was 50 times higher than the blood serum reference 
level (0.1 mg/L) [30]. In addition, experimental and epidemiological 
data identified that Cr, and particularly Cr(VI), should be considered as 
genotoxic carcinogens [31-36]. According to the International Agency 
for Research on Cancer and U.S. Environmental Protection Agency, 
Cr(VI) compounds are classified as Group 1 and Group A human 
carcinogens, respectively [34]. These findings promoted more detailed 
studies of the Cr content of prostatic tissue of healthy subjects, as well 
as of patients with different prostatic diseases, including BPH and PCa.
The effects of TEs, including Cr, are related to their concentration. 
Recorded observations range from a deficiency state, through normal 
function as biologically essential components, to an imbalance, when 
excess of one element interferes with the function of another, to 
pharmacologically active concentrations, and finally to toxic and even 
life-threatening concentrations [37]. In this context, low dose of Cr 
is an essential nutrient for the human body because it is required for 
normal carbohydrate, lipid, and protein metabolism [38,39]. However, 
significant Cr exposure may result in adverse health effects in different 
organs or tissues, including malignancy such as cancers of the lung, 
nasal and sinus cavities, larynx, stomach, bladder, kidney, testicular, 
bone, thyroid, as well as PCa [20,31-36]. However, precise molecular 
mechanisms by which this metal causes healthy cells to transform to 
malignant states have yet to be fully defined. Multiple mechanisms of 
carcinogenesis have been proposed involving oxidative stress, DNA 
damage and genomic instability, and epigenetic modulation [34].
By now, a few studies have reported the Cr content in tissue of “normal” 
and affected glands. However, further investigation has been considered 
necessary to provide a practical reference data of Cr levels in prostate 
norm and disorders, because the findings of various studies indicate 
some discrepancies.
The present study addresses the significance of Cr levels in prostatic 
tissue as a biomarker of the gland’s condition. Therefore, we 
systematically reviewed all the available relevant literature and 
performed a statistical analysis of Cr content in tissue of “normal” 
glands, which may provide valuable insight into the etiology and 
diagnosis of prostate disorders.
METHODS
Data sources and search strategy
Aiming at finding the most relevant articles for this review, a thorough 
comprehensive web search was conducted by consulting the PubMed, 
Scopus, ELSEVIER-EMBASE, Cochrane Library, and the Web of Science 
databases, as well as from the personal archive of the author collected 
between 1966 and 2020, using the key words: Prostatic TEs, prostatic 
Cr content, prostatic tissue, and their combinations. For example, the 
search terms for Cr content were: “Cr mass fraction”, “Cr content”, “Cr 
level,” “prostatic tissue Cr,” and “Cr of prostatic tissue.” The language 
of the article was not restricted. The titles from the search results 
Review Article
were evaluated closely and determined to be acceptable for potential 
inclusion criteria. Furthermore, references from the selected articles 
were examined as further search tools. Relevant studies noted for the 
each selected article were also evaluated for inclusion.
Eligibility criteria
Inclusion criteria
Only papers with quantitative data of Cr prostatic content were 
accepted for further evaluation. Studies were included if the control 
groups were healthy human males with no history or evidence of 
urological or other andrological disease and Cr levels were measured in 
samples of prostatic tissue.
Exclusion criteria
Studies were excluded if they were case reports. Studies involving 
subjects that were using Cr supplementation or Cr occupational 
exposed, as well as persons from Cr contaminated area were also 
excluded.
Data extraction
A standard extraction of data was applied, and the following available 
variables were extracted from each paper: Method of Cr determination, 
number and ages of healthy persons, sample preparation, mean and 
median of Cr levels, standard deviations of mean, and range of Cr levels. 
Abstracts and complete articles were reviewed independently, and if 
the results were different, the texts were checked once again until the 
differences were resolved.
Statistical analysis
Studies were combined based on means of Cr levels in prostatic 
tissue. The articles were analyzed and “Median of Means” and “Range 
of Means” were used to examine heterogeneity of Cr contents. The 
objective analysis was performed on data from the 28 studies, with 
1282 subjects.
RESULTS
Information about Cr levels in prostatic tissue in different prostatic 
diseases is of obvious interest, not only to understand the etiology and 
pathogenesis of prostatic diseases more profoundly but also for their 
diagnosis, particularly for PCa diagnosis and PCa risk prognosis [27,37]. 
Thus, it dictates a need for reliable values of the Cr levels in the prostatic 
tissue of apparently healthy subjects, ranging from young adult males 
to elderly persons.
Possible publications relevant to the keywords were retrieved and 
screened. A total of 1958 publications were primarily obtained, of 
which 1930 irrelevant papers were excluded. Thus, 28 studies were 
ultimately selected according to eligibility criteria that investigated 
Cr levels in tissue of normal prostates (Table 1) and these 28 
papers [7,9,11,13,14,24,26,28,29,40-58] comprised the material on 
which the review was based. A number of values for Cr mass fractions 
were not expressed on a wet mass basis by the authors of the cited 
references. However, we calculated these values using the medians of 
published data for water – 83% [59-62] and ash – 1% (on a wet mass 
basis) contents in normal prostates of adult men [42,60,63,64].
Table 1 summarizes general data from the 28 studies. The retrieved 
studies involved 1282 subjects. The ages of subjects were available 
for 22 studies and ranged from 0 to 87 years. Information about the 
analytical method and sample preparation used was available for 27 
studies. Eight studies determined Cr levels by destructive (require 
high temperature drying, ashing, acid digestion, or cut section on a 
cryomicrotome) analytical methods (Table 1): One – proton induced 
X-ray fluorescence (PIXE), one – inductively coupled plasma mass 
spectrometry (ICPMS), three – atomic emission spectrometry (AES), 
and three – synchrotron radiation-induced X-ray emission (SPIXE). 
Seven studies detected Cr level in intact prostatic tissue samples by 
nondestructive analytical method, such as neutron activation analysis 
(NAA). In 12 studies a combination of destructive and nondestructive 
methods (ICPMS and NAA) was used and results were summarized.
Fig. 1 illustrates the data set of Cr measurements in 28 studies during 
the period from 1956 to 2020.
DISCUSSION
The range of means of Cr mass fractions reported in the literature 
for “normal” prostatic tissue varies widely from 0.009 mg/kg [42] 
to 5.0 mg/kg [29] with median of means 0.0955 mg/kg of wet tissue 
(Table 1). Some maximal values of mean Cr mass fraction reported 
5.0 mg/kg [29], 1.3 [44], and 2.6 [45] were at least one order of 
magnitude higher than the median (0.0955 mg/kg of wet tissue). 
The mean ± standard deviation (M±SD) of all other published 
means was 0.102±0.056 mg/kg of wet tissue. Because values 
5.0 mg/kg [29], 1.3 [44], and 2.6 [45] were higher the level “M +20SD,” 
they can be excluded. However, without these extremal results range 
of means of Cr mass fractions for “normal” prostatic tissue remains 
very wide from 0.009 mg/kg [42] to 0.34 mg/kg [43] with median of 
means 0.095 mg/kg of wet tissue and Mmax/Mmin ratio approximately 
38 (Table 1).
This variability of reported mean values can be explained a priori by a 
dependence of Cr content on many factors, including analytical method 
imperfections, differences in “normal” prostate definitions, possible 
non-homogeneous distribution of Cr levels throughout the prostate 
gland volume, age, ethnicity, diet, smoking, alcohol intake, consuming 
supplemental TEs, and others. Not all these factors were strictly 
controlled in the cited studies. For example, in some studies the “normal” 
prostate means a gland of an apparently healthy man who had died 
suddenly, but without any morphological confirmation of “normality” 
of his prostatic tissue. In other studies, the “normal” prostate means 
a non-cancerous prostate (but hyperplastic and inflamed glands were 
included) and even a visually normal prostatic tissue adjacent to a 
prostatic malignant tumor. Some researchers used as the “normal” 
prostate the glands of patients who died from acute and chronic non-
prostatic diseases including subjects who had suffered from prolonged 
wasting illnesses. In some studies, whole glands were used for the 
investigation while in others the Cr content was measured in pieces of 
the prostate. Therefore, published data allowed us to estimate the effect 
of only some different factors on Cr content in “normal” prostate tissue.
Analytical method 
The trend line of Cr content data in “normal” prostate (Fig. 1) showed 
that an improvement of analytical technologies during last almost 
60 years did not impact significantly on the means and variability 
of reported values. Thus, in our opinion, the leading cause of inter-
observer variability was insufficient quality control of results 
in published studies. In some reported papers such destructive 
y =-0.0006x + 1.215
























Fig. 1: Data on Cr content in normal prostate tissue reported from 
1954 to 2020 without values 5.06 mg/kg [29], 1.36 mg/kg [44], 
and 2.6 mg/kg of wet tissue [45]
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analytical methods as AES [40-42] and ICP-MS [47] were used. These 
methods require ashing and acid digestion of the samples at a high 
temperature. There is evidence that use of this treatment causes 
some quantities of TEs to be lost [37,65,66]. On the other hand, the 
Cr content of chemicals used for acid digestion can contaminate the 
prostate samples. Thus, when using destructive analytical methods it 
is necessary to allow for the losses of TEs, for example, when there is 
complete acid digestion of the sample. Then, there are contaminations 
by TEs during sample decomposition, which require addition of some 
chemicals.
Such destructive analytical method as SRIXE [29,43,44] needs in 
cutting section on a cryomicrotome, and PIXE [45] – in a tissue sample 
homogenization and slice pressing. In these cases samples may be 
contaminated during sample preparation, because a blade of microtome 
and a press made of Cr-contained stainless steel needs to use [67].
It is possible to avoid these problems using non-destructive methods, 
such as NAA [7,11,24,46,48,50,52] which allow quantify Cr content in 
“normal” prostate without any sample preparation. Moreover, a good 
agreement between results obtained by both NAA and ICPMS methods 
under a strong quality control [9,13,14,26,49,51,53-58] shoved that 
in case of Cr it is possible to avoid uncertainties connected with acid 
digestion. It is, therefore, reasonable to conclude that the quality 
control of results is very important factor for using the Cr content in 
prostatic tissue as biomarkers.
Table 1: Reference data of Cr mass fractions (mg/kg wet tissue) in “normal” human prostate
Reference Method n Age range years Sample preparation Cr
M±SD Range
Tipton et al., 1954 [40] AES 8 Adult D, A 0.28 -
Koch et al., 1956 [41] AES 4 Adult AD 0.12 -
Zakutinsky et al., 1962 [28] - - - - 0.05 -
Tipton et al., 1963 [42] AES 50 Adult D, A 0.009 Median Max=0.023
Banaś et al., 2001 [29] SRIXE 5 Adult CS (NB) 5.0±1.0 -
Kwiatek et al., 2004 [43] SRIXE 3 61 CS (NB) 0.34±0.09 -
Kwiatek et al., 2005 [44] SRIXE 1 Adult CS (NB) 1.3
Guntupalli et al., 2007 [45] PIXE 27 38–68 H, Pressing 2.6±1.6 -
Zaichick and Zaichick, 2011 [46] NAA 64 13–60 Intact 0.082±0.079 0.005-0.32
9 13–20 Intact 0.082±0.077 -
28 21–40 Intact 0.078±0.068 -
27 41–60 Intact 0.087±0.077 -
Zaichick and Zaichick, 2012 [24] NAA 37 66±8 Intact 0.090±0.071 0.005–0.31
Zaichick et al., 2012 [47] ICPMS 64 13–60 AD ≤DPMS <0.085–0.32
Zaichick and Zaichick, 2013 [7] NAA 29 0–13 Intact 0.112±0.085 -
21 14–30 Intact 0.043±0.036 -
Zaichick and Zaichick, 2013 [9] 2 Methods 29 0–13 Intact 0.117±0.087 -
21 14–30 Intact 0.043±0.031 -
Zaichick and Zaichick, 2014 [48] NAA 28 21–40 Intact 0.066±0.049 0.008–0.167
27 41–60 Intact 0.087±0.075 0.005–0.31
10 61–87 Intact 0.102±0.068 0.048–0.24
Zaichick and Zaichick, 2014 [49] 2 Methods 28 21–40 Intact, AD 0.080±0.079 0.008–0.32
27 41–60 Intact, AD 0.085±0.066 0.005–0.31
10 61–87 Intact, AD 0.126±0.090 0.049–0.27
Zaichick and Zaichick, 2014 [11] NAA 29 0–13 Intact 0.16±0.13
21 14–30 Intact 0.047±0.040
50 0–30 Intact 0.11±0.11
Zaichick and Zaichick, 2014 [13] 2 Methods 16 20–30 Intact, AD 0.044±0.029 -
Zaichick and Zaichick, 2014 [14] 2 Methods 50 0–30 Intact, AD 0.11±0.12
29 0–13 Intact, AD 0.16±0.13
21 14–30 Intact, AD 0.047±0.035
Zaichick and Zaichick, 2015 [50] NAA 32 44–87 Intact 0.085±0.058 0.005–0.24
Zaichick, 2015 [51] 2 Methods 65 21–87 Intact, AD 0.088±0.071 -
Zaichick and Zaichick, 2016 [52] NAA 28 21–40 Intact 0.081±0.058 0.012–0.190
27 41–60 Intact 0.100±0.098 0.007–0.370
10 61=87 Intact 0.135±0.104 0.073–0.347
Zaichick and Zaichick, 2016 [53] 2 Methods 65 21–87 Intact, AD 0.104±0.083 0.007–0.370
28 21–40 Intact, AD 0.093±0.015 -
27 41–60 Intact, AD 0.099±0.016 -
10 61=87 Intact, AD 0.156±0.041 -
Zaichick and Zaichick, 2016 [54] 2 Methods 32 44–87 Intact, AD 0.090±0.068 -
Zaichick and Zaichick, 2016 [55] 2 Methods 37 41–87 Intact, AD 0.095±0.082 -
Zaichick and Zaichick, 2017 [26] 2 Methods 37 41–87 Intact, AD 0.095±0.082 -
Zaichick and Zaichick, 2017 [56] 2 Methods 37 41–87 Intact, AD 0.108±0.082 0.0068–0.352
Zaichick, 2017 [57] 2 Methods 37 41–87 Intact, AD 0.096±0.074 0.005–0.31
Zaichick and Zaichick, 2019 [58] 2 Methods 37 41–87 Intact, AD 0.096±0.074 0.005–0.31
Median of means 0.0955 or 0.095 (without 5.0, 1.3, 2.6)
Range of means (Mmin–Mmax) 0.0090–5.0 or 0.0090–0.34 (without 5.0, 1.3, 2.6)
Ratio Mmax/Mmin 556 or 37.8 (without 5.0, 1.3, 2.6)
All references 28
M: Arithmetic mean, SD: Standard deviation of mean, AES: Atomic emission spectrometry, SRIXE: Synchrotron radiation-induced X-ray emission, PIXE: Proton induced 
X-ray fluorescence, NAA: Neutron activation analysis, ICPMS: Inductively coupled plasma mass spectrometry; 2 Methods: NAA and ICPMS, D: Drying at high temperature, 
A: Ashing, AD: Acid digestion, CS: Cut section on a cryomicrotome, NB: Needle biopsy, H: Homogenization
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Age
In a few studies, it was found that the prostatic Cr content does not 
depend on age during lifespan. It was shown by the comparison of 
different age groups or the Pearson’s coefficient of correlation between 
age and Cr content in prostate tissue [7,9,11,14,46,48,49,52,53]. 
Androgen-independence of prostatic Cr level
There was not found any statistical significant difference between Cr 
levels in prostates of teenagers before puberty and of post-pubertal 
teenagers and young adults [7,9,11,14]. These findings allowed us to 
conclude that the Cr content in “normal” prostates does not depend 
on the level of androgens, and vice versa. However, studies on the 
association between the Cr content in “normal” prostates and the level 
of androgens in blood were not found.
Cr intake
The general population can be exposed to low levels of Cr primarily 
through consumption of food and to a lesser degree through inhalation 
of ambient air and ingestion of drinking water [33]. Vegetables (broccoli, 
green beans, and potatoes), fruits (apples, bananas, peas, ad grapes), 
kidney, liver, meats, poultry, seafood, and cheese generally contain 
the most Cr [68]. For most of the general population, dietary intake 
(50–200 μg Cr/d) represents the primary source of Cr exposure [38]. 
Elevated Cr intake may result from prescription Cr supplements. 
Other potential sources of Cr exposure include consumer products, 
automobile exhaust, and smoking, including traditional and electronic 
cigarettes and hookahs [34]. However, over the last decades, the use 
of Co-Cr hard-metal alloys in orthopedic arthroplasties has created an 
entirely new source of internal Cr exposure. Orthopedic arthroplasties 
are artificial devices made of Co-Cr alloys which are used to replace 
damaged joints in the body, for example, hip, knee, finger, and shoulder. 
If these orthopedic devices were initially mainly used by the elderly, but 
now they are used in increasing numbers across the populace. About 
0.16–0.2% of population per year in industrial countries undergo only 
total hip joint arthroplasty and the recipients are from all age groups 
ranging from 20 to 80 years of age [69]. Corrosion and wear produce 
soluble metal ions and metal debris in the form of huge numbers of 
wear particles in nanometric size, with systemic dissemination through 
lymph, and systemic vascular system [70].
Cr content in body fluids, tissues, and organs
It is known that Cr is accumulated primarily in liver, kidney, and 
muscle [70]. Mass fraction of this metal in the liver of Reference Man 
ranged from 0.005 to 0.050 (mean 0.01) mg/kg of wet tissue [30]. The 
median of prostatic Cr content means obtained in the present review 
(0.095 mg/kg of wet tissue) is almost one order of magnitude higher 
the metal level in liver. Thus, we can conclude that the prostate is a 
target organ for Cr and a small increase of Cr concentration in blood 
for a long period may associate with a great increase of this metal in 
different target organs, including the prostate.
All natural chemical elements of the Periodic System, including 
Cr, present in all subjects of biosphere [37,71,72]. During the long 
evolutional period intakes of Cr were more or less stable and organisms 
were adopted for such environmental conditions. Moreover, organisms, 
including human body, involved low doses of this metal in their 
functions. For example, Cr is biologically active as part of an oligopeptide 
– chromodulin – potentiating the effect of insulin by facilitating insulin 
binding to receptors at the cell surface [39]. The situation began 
to change after the industrial revolution, particularly, over the past 
100 years. Discovered in the 1797 year, the use of Cr and various Cr 
compounds and alloys started to become industrially important near 
the close of the 19th century. Cr is the 21st most common element found 
in the earth’s crust, but it is not found in its free metal form. Instead, it 
is principally found in chromite ore. Cr metal is obtained by heating the 
chromite ore in the presence of aluminum or silicon.
Cr and Cr compounds are consumed by the chemical, metallurgical, 
and refractory industries. Major uses for metallic Cr include chrome 
electroplating and production of stainless steel. Stainless steel is an 
alloy of iron and at least 10.5% Cr. Cr compounds are used as pigments 
for glass, ceramics, and enamels, as driers for paints, varnishes, or 
lacquers. About 90% of leather is Cr sulfate tanned. The textile industry 
uses Cr ions to adhere dyes to fabric. Kilns and furnaces use bricks 
made of chromite ore, which retains strength at high temperatures [73].
The extensive use of Cr in various industrial processes increases the 
levels of pollution in the environment. Environmental Cr pollution occurs 
mainly through a combination of air, water, and land contamination and 
is subsequently introduced into the food chain. Cr and its compounds 
are released into the air as by-products of fossil fuel combustion, waste 
incineration, and various industrial processes (e.g., aerospace products 
and parts manufacturing, pulp and paper mills, ferro Cr or Cr metal 
production) as diffused pollution [74]. Cr is discharged into the water 
in the form of wastewater from industries such as leather tanning, 
metal fabrication, and Cr plating, as well as from production of wood 
preservatives, chrome pigments (e.g., lead chromate) which are used 
in paints, printing inks, and anti-corrosive materials [74]. Cr in the soil 
may come from atmospheric deposition, sediment accumulation, and 
the potential leach ability of this metal [74].
Of the estimated 2700–2900 metric tons of Cr emitted to the 
atmosphere annually from anthropogenic sources in the United States, 
approximately one-third is in the hexavalent form [75]. The global 
demand for Cr increases constantly and, as the consequence of it, 
concentrations of this metal in the environmental media also increase. 
Thus, it is likely that Cr content in the “normal” prostate tissue will 
increase as the result of a global accumulation of Cr in the environment.
Thus, according our study for not polluted areas no one influencing 
factor could explain the variability of published means for prostatic 
Cr levels from 0.0090 mg/kg to 0.34 mg/kg in wet tissue. Moreover, 
prostate tissue Cr contents showed large variations among individuals, 
but sources of the variation remain unknown. It is reasonable to assume 
from data of our study that inaccuracy of analytical technologies 
employed caused so great variability of published means for prostatic 
Cr levels. This conclusion was supported the fact that the Certified 
Reference Materials for quality control of results were not used in 
studies reported in 1960s [40-42] and in 2000s [29,43-45].
There are some limitations in our study, which need to be taken into 
consideration when interpreting the results of this review. The sample 
size of each study was sometimes relatively small (from 1 to 65), and a 
total of 1282 “normal” controls were investigated from all 28 studies. 
As such, it is hard to draw definite conclusions about the reference 
value of the Cr content in “normal” prostate as well as about the clinical 
value of the Cr levels in “normal” prostates as a biomarker.
CONCLUSION
The present study is a comprehensive study regarding the determination 
of Cr content in “normal” human prostates. With this knowledge 
Cr levels may then be considered as a biomarker for the recognition 
of prostate disorders. The study has demonstrated that level of Cr in 
“normal” prostates depends on analytical method. Because of the 
uncertainties we have outlined, we recommend other primary studies 
be performed.
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